Jan T M van der Meer Selected Research

Jan T M van der Meer Research Topics

10	Infections 12/2023 - 01/2011
5	Endocarditis 06/2023 - 02/2008
3	Bacteremia 04/2024 - 06/2005
2	Hepatitis C 01/2019 - 04/2016
1	Communicable Diseases (Infectious Diseases) 04/2024
1	Infectious Arthritis (Septic Arthritis) 12/2022
1	Osteomyelitis 01/2019
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2019
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2016
1	Viremia 01/2016
1	Coinfection 04/2015
1	Reinfection 11/2011
1	Pain (Aches) 01/2009
1	Nephrolithiasis 12/2002
1	Chemical and Drug Induced Liver Injury 12/2002

3	Anti-Bacterial Agents (Antibiotics)IBA 12/2023 - 01/2011
3	RNA (Ribonucleic Acid)IBA 04/2015 - 11/2011
1	Rheumatoid FactorIBA 06/2023
1	Immunoglobulin M (IgM)IBA 06/2023
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2023
1	oxidized low density lipoproteinIBA 01/2019
1	N 30IBA 01/2019
1	LDL CholesterolIBA 01/2019
1	Ribavirin (Virazole)FDA LinkGeneric 04/2016
1	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA 04/2016
1	Interferon-alpha (Interferon Alfa)IBA 04/2016
1	Oraconal (Serial C)IBA 02/2008
1	Proteins (Proteins, Gene)FDA Link 02/2008
1	Vancomycin FDA LinkGeneric 06/2005
1	Nevirapine (Viramune)FDA Link 12/2002
1	Indinavir (Crixivan)FDA Link 12/2002

3	Therapeutics 01/2019 - 04/2016
1	Catheters 12/2022
1	Highly Active Antiretroviral Therapy (HAART) 01/2016
1	Aftercare (After-Treatment) 11/2011
1	Duration of Therapy 06/2011
1	Conservative Treatment 01/2009
1	Renal Dialysis (Hemodialysis) 06/2005